Medical Devices US

US Intragastric Balloon Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

US Intragastric Balloon Market Industry Trends and Forecast to 2034: Segmented by (Type, Filling, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

US · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $125.7 Mn Placeholder estimate
Estimate 2025 $137.4 Mn 44.6% of the global market
Projected 2034 $305.9 Mn 122.6% Adds $168.5 Mn over 9 forecast years
CAGR 2025–2034 9.3% Faster than 67% of 173 Medical Devices markets here
Key players 5 Companies profiled
  • US is 44.6% of the global market.
  • In North America, the largest is US (this report) at $137.4 Mn.
  • Fastest growing: Canada at 11.2% a year.
  • US ranks 1st of 2 by size in North America.

Market size projection

US

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$168.5 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Intragastric Balloon Market market size by year, US
YearMarket sizeChange that yearSince 2025
2024 (estimate) $125.7 Mn — —
2025 (base) $137.4 Mn +$11.7 Mn —
2026 (forecast) $150.2 Mn +$12.8 Mn +9.3%
2027 (forecast) $164.1 Mn +$14.0 Mn +19.5%
2028 (forecast) $179.4 Mn +$15.3 Mn +30.6%
2029 (forecast) $196.1 Mn +$16.7 Mn +42.7%
2030 (forecast) $214.3 Mn +$18.2 Mn +56%
2031 (forecast) $234.2 Mn +$19.9 Mn +70.5%
2032 (forecast) $256.0 Mn +$21.8 Mn +86.4%
2033 (forecast) $279.8 Mn +$23.8 Mn +103.7%
2034 (forecast) $305.9 Mn +$26.0 Mn +122.6%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

US Intragastric Balloon Market Analysis at a glance
Market size, 2025$137.4 Mn placeholder estimate
Forecast, 2034$305.9 Mn placeholder estimate
Growth (CAGR), 2025–20349.3% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsType, filling and end user (see all)
Key playersAllurion Technologies, Apollo Endosurgery, Spatz Medical, Obalon Therapeutics, Helioscopie (see all)
Regulator in the USFDASource: US Food and Drug Administration. Checked 14 Nov 2026.
Active clinical trials6 in the USSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the US. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The US Intragastric Balloon Market Analysis Executive Summary

Intragastric balloons are soft balloons placed in the stomach for a few months to help people eat less and lose weight without surgery.

Key segments of the intragastric Balloon market include type (Single Balloon, Dual Balloon and Swallowable Balloon) and filling (Saline-Filled and Gas-Filled).

Bar chart: US Intragastric Balloon market size, 2024–2034, placeholder estimates. $125.7 Mn in 2024, $137.4 Mn in 2025 and $305.9 Mn in 2034, 9.3% CAGR.
US Intragastric Balloon market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

US Intragastric Balloon Market Dynamics

Market Growth Drivers

Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the intragastric Balloon market. Wider insurance coverage and more doctors trained in obesity care are adding to demand.

Opportunity

Oral formulations, combination therapies and use in heart, kidney and liver disease open new growth paths for the intragastric Balloon market, especially in fast-growing emerging economies.

Market Restraints

High treatment prices, limited reimbursement, supply shortages and side effects that lead some patients to stop treatment hold back the intragastric Balloon market. Long-term safety data and lifestyle support are still needed for many patients.

Competitive Landscape for Intragastric Balloon Market in US

The intragastric Balloon market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Intragastric Balloon Market in US

Intragastric Balloon in the US: rules, payment and research

The FDA clears or approves medical devices by risk class, through 510(k) clearance, De Novo classification or premarket approval (PMA).⁠[1] Medicare covers people aged 65 and over and some younger people with disabilities, and Medicaid covers many people on low incomes; both are run with the Centers for Medicare & Medicaid Services (CMS).⁠[2] ClinicalTrials.gov lists 6 studies on Intragastric Balloon that are recruiting, active or about to start in the US.⁠[3] Obesity (adults): 41.0% of adults in 2024, the latest WHO figure for the US.⁠[4]

[1] US Food and Drug Administration. Checked 14 Nov 2026.

[2] Centers for Medicare & Medicaid Services. Checked 14 Nov 2026.

[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the US. Retrieved 12 Nov 2026.

[4] WHO Global Health Observatory, Obesity (adults) (% of adults). Retrieved 15 Nov 2026.

Policy changes and Reimbursement scenario

Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how intragastric Balloon products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in US.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Intragastric Balloon right now, from free public sources.

Clinical trials

6 active trials in the US

Recruiting, about to start, or running now.

Top trial sponsors (worldwide)

  1. Boston Scientific Corporation 2 active trials on ClinicalTrials.gov (opens in a new tab)

Source: ClinicalTrials.gov, Industry lead sponsors of active studies found with this market's trial search, worldwide. Retrieved 13 Nov 2026.

See every trial on ClinicalTrials.gov (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, WHO Global Health Observatory, World Bank. Fetched 15 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Intragastric Balloon in context

The US compared

  • Obesity (adults): 41.0% of adults (2024). World: 16.2% of adults (2024).[1]
  • Health spending per person: 13,473 US$ per person (2023). World: 1,317 US$ per person (2023).[2]
  • Doctors: 3.68 per 1,000 people (2022). World: 1.86 per 1,000 people (2022).[3]

[1] WHO Global Health Observatory, Obesity (adults) (% of adults). Retrieved 16 Nov 2026.

[2] World Bank Open Data, Health spending per person (US$ per person). Retrieved 16 Nov 2026.

[3] World Bank Open Data, Doctors (per 1,000 people). Retrieved 16 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Intragastric Balloon market in the US?
Placeholder estimate: about $137.4 Mn in 2025, rising to about $305.9 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Intragastric Balloon market in the US growing?
Placeholder estimate: about 9.3% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Intragastric Balloon market report cover?
The report splits the market by type (Single Balloon, Dual Balloon, Swallowable Balloon), filling (Saline-Filled, Gas-Filled) and end user (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Home Care Settings).
Who are the key players in the Intragastric Balloon market?
Key players include Allurion Technologies, Apollo Endosurgery, Spatz Medical, Obalon Therapeutics and Helioscopie.
What is driving the Intragastric Balloon market?
Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the intragastric Balloon market.
Who regulates Intragastric Balloon in the US?
The FDA clears or approves medical devices by risk class, through 510(k) clearance, De Novo classification or premarket approval (PMA). Source: US Food and Drug Administration. Checked 14 Nov 2026.
How is healthcare paid for in the US?
Medicare covers people aged 65 and over and some younger people with disabilities, and Medicaid covers many people on low incomes; both are run with the Centers for Medicare & Medicaid Services (CMS). Source: Centers for Medicare & Medicaid Services. Checked 14 Nov 2026.
How many clinical trials on Intragastric Balloon are running in the US?
6 studies are recruiting, active or about to start in the US, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the US. Retrieved 12 Nov 2026.
What does WHO report for the US?
Obesity (adults): 41.0% of adults in 2024, the latest WHO figure. Source: WHO Global Health Observatory, Obesity (adults) (% of adults). Retrieved 15 Nov 2026.
How many people in the US are 65 or older?
18.4% of people were 65 or older in 2025. Source: World Bank Open Data, Population ages 65 and above (% of total population), from UN population estimates. Retrieved 16 Nov 2026.
Back to Catalogue

Related Medical Devices reports in US

See all

Related on obesity and diabetes

See the topic